Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Mydecine Innovations Group Inc. was formerly known as Mydecine Innovations Group Inc. and changed its name to Noveris Health Sciences Inc. in February 2026. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.